Symbols / IRD Stock $3.91 +0.51% Opus Genetics, Inc.

Healthcare • Biotechnology • United States • NCM
IRD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. George Magrath M.B.A., M.D., M.S.
Exch · Country NCM · United States
Market Cap 322.83M
Enterprise Value 282.60M
Income -106.93M
Sales 11.98M
FCF (ttm) -39.27M
Book/sh -0.64
Cash/sh 0.74
Employees 27
Insider 10d —
IPO Nov 10, 2005
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.57
PEG —
P/S 26.94
P/B -6.09
P/C —
EV/EBITDA -6.58
EV/Sales 23.58
Quick Ratio 6.71
Current Ratio 7.13
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.31
EPS next Y -0.70
EPS Growth —
Revenue Growth -50.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-05-12
ROA -46.79%
ROE -75.95%
ROIC —
Gross Margin -179.03%
Oper. Margin -6.66%
Profit Margin 0.00%
Shs Outstand 82.57M
Shs Float 56.68M
Insider Own 11.22%
Instit Own 55.81%
Short Float 4.99%
Short Ratio 4.05
Short Interest 3.92M
52W High 5.81
vs 52W High -32.70%
52W Low 0.90
vs 52W Low 334.44%
Beta 0.55
Impl. Vol. 3.47%
Rel Volume 0.36
Avg Volume 836.70K
Volume 304.62K
Target (mean) $10.62
Tgt Median $10.00
Tgt Low $8.00
Tgt High $16.00
# Analysts 16
Recom Strong_buy
Prev Close $3.89
Price $3.91
Change 0.51%
About

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.63
Mean price target
2. Current target
$3.91
Latest analyst target
3. DCF / Fair value
$-8.56
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.91
Low
$8.00
High
$16.00
Mean
$10.63

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-04 init Guggenheim — → Buy $16
2026-05-21 init Leerink Partners — → Outperform $10
2026-05-13 main Citizens Market Outperform → Market Outperform $11
2026-04-28 init Citizens — → Market Outperform $12
2026-03-30 init Cantor Fitzgerald — → Overweight $15
2026-03-16 init Oppenheimer — → Outperform $10
2026-03-12 main Wedbush Outperform → Outperform $10
2026-03-12 main Chardan Capital Buy → Buy $11
2026-03-02 main BTIG Buy → Buy $12
2026-01-28 reit BTIG Buy → Buy $7
2026-01-20 init BTIG — → Buy $7
2025-12-10 init B. Riley Securities — → Buy $9
2025-11-25 init Piper Sandler — → Overweight $7
2025-11-13 main Chardan Capital Buy → Buy $9
2025-11-07 main Chardan Capital Buy → Buy $9
2025-10-29 init Wedbush — → Outperform $8
2025-10-16 init Chardan Capital — → Buy $9
2025-06-27 reit HC Wainwright & Co. Buy → Buy $8
2025-06-17 init LUCID CAPITAL MARKETS — → Buy $5
2025-04-11 init Craig-Hallum — → Buy $6
News
RSS: Latest IRD news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
14.20
+29.15%
10.99
-42.30%
19.05
-52.20%
39.85
Operating Revenue
14.20
+29.15%
10.99
-42.30%
19.05
-52.20%
39.85
Operating Expense
52.80
+17.15%
45.07
+52.19%
29.61
+36.94%
21.62
Research And Development
30.81
+14.75%
26.85
+52.10%
17.65
+22.97%
14.36
Selling General And Administration
21.98
+20.69%
18.21
+52.31%
11.96
+64.52%
7.27
General And Administrative Expense
21.98
+20.69%
18.21
+52.31%
11.96
+64.52%
7.27
Other Gand A
21.98
+20.69%
18.21
+52.31%
11.96
+64.52%
7.27
Total Expenses
52.80
+17.15%
45.07
+52.19%
29.61
+36.94%
21.62
Operating Income
-38.60
-13.28%
-34.07
-222.58%
-10.56
-157.96%
18.23
Total Operating Income As Reported
-38.60
+37.82%
-62.07
-487.66%
-10.56
-157.96%
18.23
EBITDA
-48.07
+16.43%
-57.52
-565.76%
-8.64
-147.43%
18.22
Normalized EBITDA
-36.56
-23.53%
-29.59
-239.38%
-8.72
-147.87%
18.22
Reconciled Depreciation
0.05
+430.00%
0.01
+66.67%
0.01
+50.00%
0.00
EBIT
-48.12
+16.35%
-57.53
-565.42%
-8.65
-147.47%
18.21
Total Unusual Items
-11.52
+58.77%
-27.93
-35010.00%
0.08
—
Total Unusual Items Excluding Goodwill
-11.52
+58.77%
-27.93
-35010.00%
0.08
—
Special Income Charges
0.00
+100.00%
-28.00
0.00
—
Other Special Charges
—
28.00
—
—
Net Income
-49.59
+13.80%
-57.53
-476.13%
-9.99
-155.83%
17.89
Pretax Income
-49.59
+13.80%
-57.53
-476.82%
-9.97
-154.79%
18.20
Net Non Operating Interest Income Expense
-1.47
0.00
+100.00%
-1.33
-14655.56%
-0.01
Interest Expense Non Operating
1.47
0.00
-100.00%
1.33
+14655.56%
0.01
Net Interest Income
-1.47
0.00
+100.00%
-1.33
-14655.56%
-0.01
Interest Expense
1.47
0.00
-100.00%
1.33
+14655.56%
0.01
Other Income Expense
-9.53
+59.39%
-23.46
-1323.68%
1.92
+13792.86%
-0.01
Other Non Operating Income Expenses
1.99
-55.50%
4.47
+143.33%
1.84
+13221.43%
-0.01
Gain On Sale Of Security
-11.52
-16093.06%
0.07
-10.00%
0.08
—
Tax Provision
0.00
0.00
-100.00%
0.01
-96.19%
0.32
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+1135.29%
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
0.02
0.00
Net Income Including Noncontrolling Interests
-49.59
+13.80%
-57.53
-476.13%
-9.99
-155.83%
17.89
Net Income From Continuing Operation Net Minority Interest
-49.59
+13.80%
-57.53
-476.13%
-9.99
-155.83%
17.89
Net Income From Continuing And Discontinued Operation
-49.59
+13.80%
-57.53
-476.13%
-9.99
-155.83%
17.89
Net Income Continuous Operations
-49.59
+13.80%
-57.53
-476.13%
-9.99
-155.83%
17.89
Normalized Income
-38.08
-28.62%
-29.60
-194.59%
-10.05
-156.18%
17.89
Net Income Common Stockholders
-49.59
+13.80%
-57.53
-476.13%
-9.99
-155.83%
17.89
Diluted EPS
-0.80
+62.79%
-2.15
-367.39%
-0.46
-152.87%
0.87
Basic EPS
-0.80
+62.79%
-2.15
-367.39%
-0.46
-151.11%
0.90
Basic Average Shares
62.22
+132.91%
26.72
+23.74%
21.59
+8.32%
19.93
Diluted Average Shares
62.22
+132.91%
26.72
+23.74%
21.59
+4.82%
20.60
Diluted NI Availto Com Stockholders
-49.59
+13.80%
-57.53
-476.13%
-9.99
-155.83%
17.89
Total Other Finance Cost
—
—
1.33
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
50.24
+36.30%
36.86
-31.67%
53.95
+10.12%
48.99
Current Assets
50.04
+36.69%
36.61
-32.14%
53.95
+10.13%
48.99
Cash Cash Equivalents And Short Term Investments
45.09
+48.70%
30.32
-39.97%
50.52
+18.35%
42.68
Cash And Cash Equivalents
45.09
+48.71%
30.32
-39.96%
50.50
+18.45%
42.63
Other Short Term Investments
0.00
-100.00%
0.00
-86.67%
0.01
-69.39%
0.05
Receivables
3.17
-45.17%
5.77
+147.41%
2.33
-51.90%
4.85
Accounts Receivable
2.00
-44.01%
3.56
+284.77%
0.93
-28.66%
1.30
Other Receivables
1.17
-47.03%
2.21
+57.00%
1.41
-60.39%
3.55
Prepaid Assets
—
—
1.00
-27.39%
1.37
Other Current Assets
1.79
+247.18%
0.52
-53.14%
1.10
+1273.75%
0.08
Total Non Current Assets
0.20
-21.03%
0.25
0.00
-100.00%
0.01
Net PPE
0.20
-21.03%
0.25
0.00
-100.00%
0.01
Gross PPE
—
—
0.03
+0.00%
0.03
Accumulated Depreciation
—
—
-0.03
-31.58%
-0.02
Machinery Furniture Equipment
—
—
0.01
+0.00%
0.01
Other Properties
—
—
0.02
+0.00%
0.02
Total Liabilities Net Minority Interest
34.90
+15.78%
30.14
+645.62%
4.04
+46.82%
2.75
Current Liabilities
7.78
-31.11%
11.29
+179.44%
4.04
+46.82%
2.75
Payables And Accrued Expenses
7.78
-31.10%
11.29
+184.60%
3.97
+44.13%
2.75
Payables
3.29
+4.61%
3.15
+46.21%
2.15
+55.56%
1.38
Accounts Payable
3.29
+4.61%
3.15
+46.21%
2.15
+101.40%
1.07
Current Accrued Expenses
4.49
-44.90%
8.14
+348.76%
1.81
+32.58%
1.37
Total Tax Payable
—
—
0.00
-100.00%
0.32
Income Tax Payable
—
—
0.00
-100.00%
0.32
Current Debt And Capital Lease Obligation
—
—
—
—
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Other Current Liabilities
—
0.00
-97.30%
0.07
—
Total Non Current Liabilities Net Minority Interest
27.11
+43.89%
18.84
0.00
0.00
Long Term Debt And Capital Lease Obligation
1.13
—
—
—
Long Term Debt
1.13
—
—
—
Preferred Securities Outside Stock Equity
0.00
-100.00%
18.84
0.00
—
Stockholders Equity
15.35
+128.26%
6.72
-86.53%
49.91
+7.93%
46.24
Common Stock Equity
15.35
+128.26%
6.72
-86.53%
49.91
+7.93%
46.24
Capital Stock
0.01
+133.33%
0.00
+50.00%
0.00
+0.00%
0.00
Common Stock
0.01
+133.33%
0.00
+50.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
69.89
+121.36%
31.57
+31.68%
23.98
+14.94%
20.86
Ordinary Shares Number
69.89
+121.36%
31.57
+31.68%
23.98
+14.94%
20.86
Additional Paid In Capital
203.93
+39.95%
145.72
+10.92%
131.37
+11.60%
117.72
Retained Earnings
-188.59
-35.68%
-139.00
-70.62%
-81.47
-13.97%
-71.48
Total Equity Gross Minority Interest
15.35
+128.26%
6.72
-86.53%
49.91
+7.93%
46.24
Total Capitalization
16.48
+145.05%
6.72
-86.53%
49.91
+7.93%
46.24
Working Capital
42.26
+66.95%
25.32
-49.27%
49.91
+7.94%
46.23
Invested Capital
16.48
+145.05%
6.72
-86.53%
49.91
+7.93%
46.24
Total Debt
1.13
—
—
—
Net Tangible Assets
15.35
+128.26%
6.72
-86.53%
49.91
+7.93%
46.24
Tangible Book Value
15.35
+128.26%
6.72
-86.53%
49.91
+7.93%
46.24
Derivative Product Liabilities
25.98
0.00
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-35.25
-37.84%
-25.58
-2200.00%
-1.11
-107.77%
14.31
Cash Flow From Continuing Operating Activities
-35.25
-37.84%
-25.58
-2200.00%
-1.11
-107.77%
14.31
Net Income From Continuing Operations
-49.59
+13.80%
-57.53
-476.13%
-9.99
-155.83%
17.89
Depreciation Amortization Depletion
0.05
+430.00%
0.01
+66.67%
0.01
+50.00%
0.00
Depreciation
0.05
+430.00%
0.01
+66.67%
0.01
+50.00%
0.00
Depreciation And Amortization
0.05
+430.00%
0.01
+66.67%
0.01
+50.00%
0.00
Other Non Cash Items
1.52
-94.56%
28.00
+2008.43%
1.33
—
Stock Based Compensation
3.40
+1.10%
3.36
-4.22%
3.51
+94.24%
1.81
Operating Gains Losses
11.52
+557.13%
-2.52
-3048.75%
-0.08
—
Gain Loss On Investment Securities
11.52
+16093.06%
-0.07
+10.00%
-0.08
—
Unrealized Gain Loss On Investment Securities
0.00
-84.62%
0.01
-61.76%
0.03
-80.00%
0.17
Gain Loss On Sale Of PPE
0.00
+100.00%
-2.45
0.00
—
Change In Working Capital
-2.15
-169.71%
3.09
-24.19%
4.08
+173.38%
-5.55
Change In Receivables
2.61
+175.81%
-3.44
-236.63%
2.52
+151.90%
-4.85
Changes In Account Receivables
1.57
+159.46%
-2.64
-808.87%
0.37
+128.66%
-1.30
Change In Prepaid Assets
-1.27
-300.79%
0.63
+79.10%
0.35
+354.68%
-0.14
Change In Payables And Accrued Expense
-3.49
-159.17%
5.89
+389.21%
1.21
+312.90%
-0.57
Change In Accrued Expense
-3.50
-161.59%
5.67
+4513.82%
0.12
+341.18%
-0.05
Change In Payable
0.01
-96.82%
0.22
-79.67%
1.08
+310.10%
-0.52
Change In Account Payable
0.01
-96.82%
0.22
-79.67%
1.08
+310.10%
-0.52
Investing Cash Flow
0.00
-100.00%
1.21
0.00
0.00
Cash Flow From Continuing Investing Activities
0.00
-100.00%
1.21
0.00
0.00
Gain Loss On Sale Of Business
—
-2.45
0.00
—
Net Other Investing Changes
—
1.21
—
—
Financing Cash Flow
50.02
+1095.01%
4.19
-53.38%
8.98
+137.16%
3.79
Cash Flow From Continuing Financing Activities
50.02
+1095.01%
4.19
-53.38%
8.98
+137.16%
3.79
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-0.54
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
0.00
+100.00%
-0.54
Long Term Debt Issuance
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Short Term Debt Issuance
—
—
—
0.00
Short Term Debt Payments
—
—
0.00
+100.00%
-0.54
Net Short Term Debt Issuance
—
—
0.00
+100.00%
-0.54
Net Common Stock Issuance
34.63
+683.88%
4.42
-52.12%
9.23
+108.38%
4.43
Common Stock Payments
-0.15
-92.41%
-0.08
0.00
—
Repurchase Of Capital Stock
-0.15
-92.41%
-0.08
0.00
—
Proceeds From Stock Option Exercised
16.69
0.00
-100.00%
0.03
+11.11%
0.03
Net Other Financing Charges
-1.30
-460.78%
-0.23
+16.55%
-0.28
-112.21%
-0.13
Changes In Cash
14.77
+173.19%
-20.18
-356.51%
7.87
-56.54%
18.10
Beginning Cash Position
30.32
-39.96%
50.50
+18.45%
42.63
+73.78%
24.53
End Cash Position
45.09
+48.71%
30.32
-39.96%
50.50
+18.45%
42.63
Free Cash Flow
-35.25
-37.84%
-25.58
-2200.00%
-1.11
-107.77%
14.31
Interest Paid Supplemental Data
0.00
0.00
0.00
-100.00%
0.01
Income Tax Paid Supplemental Data
0.00
0.00
-100.00%
0.34
0.00
Common Stock Issuance
34.78
+673.49%
4.50
-51.26%
9.23
+108.38%
4.43
Issuance Of Capital Stock
34.78
+673.49%
4.50
-51.26%
9.23
+108.38%
4.43
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category